{"type":"trials","record":{"id":42129,"source_id":"clinicaltrials-gov","external_id":"NCT03382587","title":"Observational Study to Assess Intravitreal Aflibercept Injections Used in a \"Treat and Extend\" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients","brief_summary":"The purpose of this observational study lies in the analysis of a treat-and-extend injection scheme with intravitreal aflibercept (i.e. injection into the eye), as applied in routine practice in previously untreated patients diagnosed with wet age-related macular degeneration.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Bayer","enrollment":163,"countries":["Switzerland"],"start_date":"2017-12-05","completion_date":"2018-11-27","last_update_date":"2023-06-05","source_url":"https://clinicaltrials.gov/study/NCT03382587","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ASTERIA","age_range":"55 Years","comparator":null,"organization":"Bayer","interventions":["Aflibercept (Eylea, BAY86-5321)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters (ETDRS…","Mean change from baseline in best-corrected visual acuity (in Early Treatment Diabetic Retinopathy Study (ETDRS) letter…","Mean change in best-corrected visual acuity in relation to the number of injections administered — Baseline and at 12 m…","Mean interval between injections — At 12 and 24 months","Reasons for the interval length — At 12 and 24 months","Frequency of disease reactivation — Baseline and at 12 months; Baseline and at 24 months","Proportion of eyes gaining or losing ≥ 15 Early Treatment Diabetic Retinopathy Study letters compared to baseline — Bas…","Mean changes from baseline in central retinal thickness (CRT) — Baseline and at 3 months; Baseline and at 12 months; Ba…","Changes from baseline in retinal fluid — Baseline and at 12 months; Baseline and at 24 months","Reasons for termination of therapy (including subsequent therapy at time of discontinuation) — At 12 and 24 months","Severity of disease reactivation — Baseline and at 12 months; Baseline and at 24 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Aflibercept (Eylea, BAY86-5321)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03382587","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2017-12-05 to 2018-11-27","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.924Z","intervention":["Aflibercept (Eylea, BAY86-5321)"],"participants":163,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters (ETDRS…","Mean change from baseline in best-corrected visual acuity (in Early Treatment Diabetic Retinopathy Study (ETDRS) letter…","Mean change in best-corrected visual acuity in relation to the number of injections administered — Baseline and at 12 m…","Mean interval between injections — At 12 and 24 months","Reasons for the interval length — At 12 and 24 months","Frequency of disease reactivation — Baseline and at 12 months; Baseline and at 24 months","Proportion of eyes gaining or losing ≥ 15 Early Treatment Diabetic Retinopathy Study letters compared to baseline — Bas…","Mean changes from baseline in central retinal thickness (CRT) — Baseline and at 3 months; Baseline and at 12 months; Ba…","Changes from baseline in retinal fluid — Baseline and at 12 months; Baseline and at 24 months","Reasons for termination of therapy (including subsequent therapy at time of discontinuation) — At 12 and 24 months","Severity of disease reactivation — Baseline and at 12 months; Baseline and at 24 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42129","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}